ACCESS Newswire·Nov 11, 2026, 9:00 AM ET

Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds

Aptevo Therapeutics Inc. entered into warrant inducement letter agreements with holders of existing common warrants to exercise up to 2,777,778 shares at a reduced price of $1.08 per share.
In exchange for the cash exercises, the Company will issue new unregistered Inducement Warrants allowing the purchase of up to 13,888,890 shares at $1.08 per share.
The Inducement Warrants become exercisable after stockholder approval and will expire five years after their initial exercise date.
Gross proceeds from the transaction are expected to total approximately $3.0 million before fees.
Roth Capital Partners is acting as the financial advisor for the transaction.
The transaction is expected to close on or about November 12, 2026, subject to customary conditions.
Net proceeds will be used for working capital purposes.
The Inducement Warrants were offered in a private placement exempt from Securities Act registration, though the Company intends to file a registration statement for resale of underlying stock.
Aptevo is a clinical-stage biotechnology company developing multispecific immuno-oncology therapeutics, including its lead candidate mipletamig for acute myeloid leukemia.
The Company's pipeline includes APVO451 for solid tumors and a collaboration with Niowave on radiopharmaceutical programs targeting nectin-4.
Preclinical molecules are expected to advance into IND-enabling studies in 2027.